Trump Signs Order Fast-Tracking Psychedelic Drugs as Mental Health Treatment

An executive order backing ibogaine and other psychedelic research marks one of the more unexpected policy turns of the current administration, landing somewhere between Silicon Valley wellness culture and veterans' advocacy.

President Trump signed an executive order directing federal agencies to accelerate research into psychedelic-assisted therapies.
Ibogaine, a plant-derived compound long illegal under federal law, is among the substances named for fast-tracked access.
Proponents have framed the push largely around treatment-resistant PTSD in military veterans.
The order represents a notable departure from the administration's broader tough-on-drugs posture.
Psychedelic therapy has been gaining clinical momentum since Oregon and Colorado moved to regulate psilocybin at the state level.

It is the kind of policy announcement that stops a scroll. An administration that has otherwise leaned hard into law-and-order drug messaging quietly signed an executive order in May 2026 directing federal agencies to fast-track research into psychedelic-assisted treatments — including ibogaine, a compound derived from an African shrub that has been a Schedule I controlled substance since 1970.

The White House framing leaned heavily on veterans. Ibogaine has circulated in military and first-responder communities for years as an off-label, often overseas treatment for PTSD and traumatic brain injury, with a small but vocal cohort of advocates arguing it does what conventional antidepressants do not. That constituency gave the order its political cover, positioning what might otherwise read as a wellness-culture concession as a national-service issue instead.

The broader psychedelic research wave has been building in clinical settings for the better part of a decade. Johns Hopkins opened a dedicated psychedelic research center in 2019. The FDA granted psilocybin “breakthrough therapy” designation for depression. Oregon began licensed psilocybin service centers in 2023. The movement had been advancing through blue-state ballot boxes and research hospitals — not, until now, through Republican executive action.

What the order actually compels versus recommends will depend on implementation timelines still being worked out across HHS and the VA. Researchers in the field told the Guardian podcast on May 12th that federal scheduling remains the central bottleneck, and an executive order does not itself reschedule a substance. The next visible marker will be whether agency rulemaking follows within the fiscal year.